- ARE expects its AFFO/share for the full year to be between $9.16 and $9.36, with analysts estimating around $9.29.
- Projected EPS has been adjusted to a range of $1.36 to $1.56, down from the previous range of $2.57 to $2.77, and compared to an analyst estimate of $2.62.
- FFO/share guidance has been lowered to between $8.51 and $8.73, compared to prior expectations of $9.23 to $9.43, with an estimate of $9.29.
- First quarter AFFO/share was reported at $2.30, slightly down from $2.35 in the same period last year, but above the estimate of $2.28.
- Revenue for the first quarter was $758.2 million, a decrease of 1.4% year-over-year, but slightly above the estimated $756.4 million.
- ARE reported a loss per share of 7.0 cents for the first quarter, a significant drop from the EPS of 97 cents in the previous year, and below the estimate of 69 cents EPS.
- The reduced guidance for 2025 FFO/share is partly due to “slower than anticipated re-leasing of expiring spaces and lease-up of vacancy in our operating portfolio and our development and redevelopment pipeline.”
- Analysts’ ratings include 5 buys and 9 holds, with no sell recommendations.
“`
A look at Alexandria Real Estate Equities Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 5 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Alexandria Real Estate Equities has received high ratings in Value and Dividend categories, indicating a positive long-term outlook for investors. The company’s strong performance in these areas suggests that it offers good value for investors and has a solid dividend yield. However, the Growth, Resilience, and Momentum scores are slightly lower, implying that there may be room for improvement in these areas. Alexandria Real Estate Equities specializes in acquiring, managing, and developing office and laboratory properties, primarily catering to pharmaceutical, biotechnology, and research institutions. With properties located in key regions such as California, Washington D.C., and New England, the company has a diverse portfolio with potential for growth.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
